Logo Image

Optimizing Frontline Treatment Strategies for the Management of EGFRm NSCLC

Experts featured in this series.

EP. 1: MARIPOSA Trial: EGFR-Mutant Lung Cancer Frontline Strategies

ByEdgardo Santos, MD, FACP, FASCO,Misako Nagasaka, MD, PhD,Estelamari Rodriguez, MD, MPH,Luis Raez, MD,Mary Jo Fidler, MD,Hatim Husain, MD,Jonathan Riess, MD, MS
Published: | Updated:

Panelists discuss the pivotal MARIPOSA trial, which examined combining amivantamab with lazertinib versus osimertinib monotherapy, showing improvements in progression-free survival (23.7 vs. 16.6 months), overall survival, CNS efficacy, and particularly strong benefits in high-risk subgroups such as TP53-mutant patients. Safety data from the trial highlighted the importance of prophylactic measures, especially for rash and other adverse events, noting that with current prophylaxis protocols, serious toxicity rates have been significantly reduced compared to the original study.

Experts featured in this series.

EP. 2: MARIPOSA Prophylaxis, Biomarkers, and CNS Debate

ByEdgardo Santos, MD, FACP, FASCO,Misako Nagasaka, MD, PhD,Estelamari Rodriguez, MD, MPH,Luis Raez, MD,Mary Jo Fidler, MD,Hatim Husain, MD,Jonathan Riess, MD, MS
Published: | Updated:

The COPERNICUS study, an ongoing phase two trial, evaluated amivantamab-based regimens in EGFR-mutant non-small cell lung cancer across two cohorts, first-line and post-osimertinib progression, with a key focus on implementing mandatory prophylactic skin and DVT regimens, resulting in dramatically lower rash rates (4% grade 3+) compared to the original MARIPOSA trial.